Company: APXIF
Filing Date: 2025-06-13
Form Type: F-4/A
Source: 0001213900-25-054324
Chunk: 646

Company: APx Acquisition Corp. I
Filing Date: 2025-06-13
Form: F-4/A
Chunk 646
---
     |            — |     |        — |
| Current                                           |     |      251,729 |     |   25,908 |
| Total                                             |     |      251,729 |     |   25,908 |

____________ (*)As of December 31, 2024, trade receivables include: CIBIC US$248,504, Bioceres S.A. US$2,690 and Heritas Ltd. US$535. As of June 30, 2024, trade receivables include: CIBIC US$18,056; Meyerlab S.A. US$4,351 and Bioceres S.A. US$3,501. See Note 20 — Related parties. Management evaluates the recoverability of the receivables and, where appropriate, records the corresponding write -offs. Based on the evaluation, there are no material expected credit losses as of December 31 and June 30 2024. 10. Cash and cash equivalents

|                                 |     |        As of 
 December 31, 
         2024 |     |    As of 
 June 30, 
     2024 |
|:--------------------------------|:----|-------------:|:----|---------:|
| Bank accounts                   |     |        4,604 |     |   28,900 |
| Short term investments          |     |           34 |     |   12,827 |
| Total cash and cash equivalents |     |        4,638 |     |   41,727 |

11. Shareholder’s deficit As of December 31, 2024, the Group reports a shareholders’ deficit, reflecting a net negative equity position primarily driven by accumulated losses. The main concepts are detailed as follows: Share Capital The Company’s issued and fully paid share capital as of December 31, 2024, amounts to US$3,000, representing 30,000,000 registered common shares with a par value of US$0.0001 per share. Each common share carries one voting right. As of June 30, 2024, the capital of OmnigenicsAI amounts to US$3,000, representing 30,000,000 registered common shares with a par value of AR$0.0001 per share. Each common share carries one voting right. See Note 1 for details of the reorganization of Héritas S.A.U. into OmnigenicsAI Corp.

|